IRIS
TAGLIAFERRI, PIEROSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.840
AS - Asia 5.574
EU - Europa 2.510
SA - Sud America 1.274
AF - Africa 133
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 22
Totale 17.378
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.504
SG - Singapore 2.578
CN - Cina 1.234
IT - Italia 1.120
BR - Brasile 966
IN - India 580
VN - Vietnam 573
GB - Regno Unito 333
SE - Svezia 332
DE - Germania 262
CA - Canada 239
HK - Hong Kong 128
AR - Argentina 107
FI - Finlandia 96
BD - Bangladesh 78
ID - Indonesia 77
NL - Olanda 62
MX - Messico 57
EC - Ecuador 53
IQ - Iraq 49
RU - Federazione Russa 49
ZA - Sudafrica 43
CO - Colombia 39
FR - Francia 37
PK - Pakistan 37
UA - Ucraina 35
ES - Italia 33
JP - Giappone 33
JO - Giordania 32
PY - Paraguay 30
RO - Romania 30
VE - Venezuela 26
TR - Turchia 25
CL - Cile 23
EG - Egitto 22
EU - Europa 22
PL - Polonia 21
SA - Arabia Saudita 21
IR - Iran 19
AU - Australia 16
PE - Perù 16
AT - Austria 15
CZ - Repubblica Ceca 15
MA - Marocco 14
KE - Kenya 13
AE - Emirati Arabi Uniti 12
LT - Lituania 11
MY - Malesia 10
NG - Nigeria 10
PT - Portogallo 10
TN - Tunisia 10
UZ - Uzbekistan 10
EE - Estonia 9
UY - Uruguay 9
IE - Irlanda 8
PH - Filippine 8
ET - Etiopia 7
IL - Israele 7
KR - Corea 7
LB - Libano 7
AZ - Azerbaigian 6
BG - Bulgaria 6
GT - Guatemala 6
HN - Honduras 6
DO - Repubblica Dominicana 5
KZ - Kazakistan 5
NP - Nepal 5
AL - Albania 4
CH - Svizzera 4
CR - Costa Rica 4
CU - Cuba 4
CY - Cipro 4
HR - Croazia 4
NZ - Nuova Zelanda 4
SN - Senegal 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
BO - Bolivia 3
DZ - Algeria 3
GE - Georgia 3
JM - Giamaica 3
LK - Sri Lanka 3
PA - Panama 3
PS - Palestinian Territory 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
GY - Guiana 2
HU - Ungheria 2
KG - Kirghizistan 2
KI - Kiribati 2
KW - Kuwait 2
LV - Lettonia 2
OM - Oman 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
BB - Barbados 1
BE - Belgio 1
BJ - Benin 1
Totale 17.360
Salva come PNG Salva come JPEG
Città #
San Jose 1.473
Chandler 826
Singapore 793
Ashburn 721
Santa Clara 437
Hefei 399
Bengaluru 396
Dallas 382
Milan 366
Lawrence 351
Princeton 351
Chicago 245
Ho Chi Minh City 221
London 219
Munich 198
Wilmington 190
Beijing 187
Ottawa 160
Des Moines 118
Hong Kong 118
Catanzaro 108
Hanoi 108
São Paulo 87
Turku 66
Los Angeles 64
Boardman 62
New York 51
Shanghai 45
Rome 38
Naples 35
Pune 35
Rio de Janeiro 35
Norwalk 34
Council Bluffs 31
Guangzhou 31
Brooklyn 29
Haiphong 29
Helsinki 29
San Francisco 29
Da Nang 28
Redmond 28
Montreal 27
The Dalles 27
Chennai 24
Amman 23
Tokyo 23
Redwood City 22
Warsaw 22
Manchester 21
Thái Bình 20
Atlanta 19
Curitiba 19
Dhaka 19
Baghdad 18
Orem 18
Parma 18
Columbus 16
Mexico City 16
San Nicola Manfredi 16
Shenzhen 16
Stockholm 16
Amsterdam 15
Biên Hòa 15
Guayaquil 15
Johannesburg 15
Phoenix 15
Porto Alegre 15
Toronto 15
Horia 14
Salvador 14
Seattle 14
Belo Horizonte 13
Quito 13
Reggio Calabria 13
Augusta 12
Cape Town 12
Carbonia 12
Cosenza 12
Nairobi 12
Palermo 12
Spezzano della Sila 12
Boston 11
Campinas 11
Delhi 11
Frankfurt am Main 11
Hanover 11
Jakarta 11
Madrid 11
Mountain View 11
Olomouc 11
Recife 11
Ankara 10
Brasília 10
Charlotte 10
Denver 10
Guarulhos 10
Jeddah 10
Lima 10
Manaus 10
Ninh Bình 10
Totale 10.023
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 454
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 138
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 110
miR-22 suppresses DNA ligase III addiction in multiple myeloma 102
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 98
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 93
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 87
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 86
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 84
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 82
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 81
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 79
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 78
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 78
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 78
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 75
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 74
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 74
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 74
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 74
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 74
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 73
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 73
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 73
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 72
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 72
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 71
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 70
Fetal ontogeny and tumor expression of the early thymic antigen UN1 70
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 70
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 69
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 68
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 68
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 67
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 67
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 67
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 66
Mir-34: a new weapon against cancer? 65
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 65
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 64
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 64
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 64
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 64
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 61
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 61
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 61
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 61
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 61
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 61
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 61
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo 60
IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells 60
miR-221/222 inhibitors for the treatment of multiple myeloma 60
Modeling UGT2B7 and NR1I3 genes through multilayer network to highlight hidden link with taxane neurotoxicity 59
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 59
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 59
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 59
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 58
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 58
Anti-myeloma activity of miR-125 mimics 58
COOPERATIVE ANTIPROLIFERATIVE EFFECTS OF 8-CHLORO-CYCLIC AMP AND 528 ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY ON HUMAN CANCER-CELLS 57
CARDIOVASCULAR MONITORING OF DRUG-RESISTANT LYMPHOMA PATIENTS TREATED WITH EPOCH CHEMOTHERAPY PLUS HIGH-DOSE VERAPAMIL IN CONTINUOUS-INFUSION 57
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives 57
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 57
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 57
Mir-221/222 are promising targets for innovative anticancer therapy 56
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation 56
PEGylated Aqueous core PLA-nanocapsules as efficacious gene delivery vehicle 56
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 56
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 56
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 56
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 56
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 56
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma 56
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 55
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 55
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 55
2 CLASSES OF CAMP ANALOGS SYNERGISTICALLY INHIBIT P21 RAS PROTEIN-SYNTHESIS AND PHENOTYPIC TRANSFORMATION OF NIH/3T3 CELLS TRANSFECTED WITH HA-MUSV DNA 55
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 55
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 55
The non-coding RNA landscape of plasma cell dyscrasias 55
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells (CO-FIRST AUTHOR) 54
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 54
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 54
The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. 54
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 54
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 54
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration - Antitumor activity and immunomodulatory effects 54
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 54
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 54
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates 54
Proteomic profiling of inherited breast cancer: Identification of molecular targets for early detection, prognosis and treatment, and related bioinformatics tools 54
Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC) 53
Severe Hemodynamic Instability in a Young Pregnant Woman with Massive Pericardial Effusion and Pulmonary Embolism Secondary to Primary Mediastinal Non-Hodgkin's Lymphoma 53
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 53
5-AZA-2'-DEOXYCYTIDINE INDUCES GROWTH-INHIBITION AND UP-REGULATION OF EPIDERMAL GROWTH-FACTOR RECEPTOR ON HUMAN EPITHELIAL CANCER-CELLS 53
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 53
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells 53
In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma 53
Totale 6.907
Salva come PNG Salva come JPEG
Categoria #
all - tutte 173.763
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 173.763
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021119 0 0 0 0 0 0 0 0 0 69 44 6
2021/2022979 19 6 12 286 57 19 31 202 96 92 146 13
2022/20232.607 722 77 85 210 279 230 13 167 395 162 217 50
2023/20241.366 311 135 116 94 98 321 41 53 15 48 61 73
2024/20254.168 563 250 184 127 234 521 108 155 486 267 423 850
2025/20267.883 412 897 819 1.510 850 326 1.174 486 1.003 406 0 0
Totale 17.673